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The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary
Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host
disease (GVHD). Topics covered in that inaugural effort included the prevention and management of in-
fections and common complications of chronic GVHD, as well as recommendations for patient education and
appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further
organ-speciﬁc reﬁnements to these guidelines. Minimum frequencies are suggested for monitoring key pa-
rameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to
existing late effects consensus guidelines is advised. Using the framework of the prior consensus, the 2014
NIH recommendations are organized by organ or other relevant systems and graded according to the strength
and quality of supporting evidence.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION severity and clinical course. Prolonged systemic immuno-
Chronic graft-versus-host disease (GVHD) is character-
ized by pleomorphic clinical manifestations with varyingdgments on page 1182.
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ty for Blood and Marrow Transplantation.suppressive treatment, including corticosteroids, is neces-
sary to control disease severity and decrease the risk of
nonrelapse mortality. Disease and treatment targeting the
immune system causes delayed immune reconstitution with
a high risk of infections and other related complications.
Furthermore, the refractory nature of underlying ﬁbrosis and
limited success of systemic immunomodulatory treatments
lead to signiﬁcant persistence of morbidity for prolonged
P.A. Carpenter et al. / Biol Blood Marrow Transplant 21 (2015) 1167e11871168periods of time. Thus, ancillary therapy and supportive care
become central components in the long-term management
of chronic GVHD after allogeneic hematopoietic cell trans-
plantation (HCT).
As in the 2005 National Institutes of Health (NIH)
consensus framework, “ancillary therapy and supportive
care” embraces the most frequent topical immunosuppres-
sive or anti-inﬂammatory interventions and any other in-
terventions directed at organ-speciﬁc control of symptoms or
complications resulting from GVHD and its therapy. Also
included in this deﬁnition are educational, preventive, and
psychosocial interventions with this same objective. Several
important aspects of good follow-up care, such asmonitoring
for and management of certain medication toxicities (eg, hy-
pertension, hyperlipidemia, renal dysfunction, seizures, etc.)
and problems not directly related to chronic GVHD (eg, iron
overload, psychosocial adaptation) fall outside the scope of
this document. General screening and preventive policies for
survivors of HCT are summarized elsewhere [1,2].METHODS
The working group searched the Medline (PubMed) database using a
broad search strategy to identify studies related to prevention and manage-
ment of infections, vaccinations, and common complications of chronic
GVHD, patient education, and appropriate long-term follow-up and moni-
toring. The primary search was conducted using “graft-versus-host disease,”
“chronic,” “bloodandmarrowtransplantation,”andavarietyof speciﬁc terms
to capture pertinent organ-speciﬁc focus (eg, “ocular,” “oral,” etc.). Relevant
references in the publications were also reviewed. In general, studies with
cohorts including fewer than 20 patients, case reports, and studies of agents
that are not commercially available were excluded from consideration.
Recommendations are organized according to an evidence-based sys-
tem to reﬂect the strength of recommendations and the quality of evidence
supporting them (Appendix 1). A version of this document posted on the
Internet includes hyperlinks to Supplements 2-11 that provide additional
organ-speciﬁc dispensary and other relevant information.
The 2014 international NIH Ancillary Therapy and Supportive Care
Working Group was ﬁrst subdivided into organ-speciﬁc subgroups, each of
which was charged with the purpose of reviewing all new evidence since
2005. The subgroups subsequently came together to discuss all relevant new
ﬁndings. Final recommendations were developed after discussion with the
steering committee (Appendix 2). Overall, the percentages of level I and II
evidence-based recommendations have not changed from 2006 to 2014
(Figure 1).
A summary of the major changes to the 2006 NIH Ancillary and Sup-
portive Care Consensus Recommendations is shown in Supplement 1. The
Working Group emphasizes that the recommendations in this document
represent a wide variety of generally accepted current medical practices.
Good clinical judgment and individual circumstances should determine
appropriate interventions for speciﬁc patients.SUMMARY OF RECOMMENDATIONS
Table 1 provides a summary of ancillary therapy and
supportive care interventions, categorized by organFigure 1. Distribution of NIH Consensus Ancillary and Supportive Care Rec-
ommendations based on quality of evidence compared to 2006 Consensus. The
number of recommendations made in 2006 was 100 and in 2014, it was 123.system. Table 2 provides a summary of general moni-
toring recommended for patients diagnosed with chronic
GVHD.
SKIN AND APPENDAGES
Ancillary and supportive care of the skin and appendages
focuses on prevention, management of manifestations such
as pruritus, rash, pain, dyspigmentation and limited range of
motion (ROM), as well as topical care for erosions, ulcera-
tions, and superinfection (Table 3). Topical therapy plays an
important role in alleviating symptoms and treating com-
plications caused by loss of skin integrity and immunosup-
pression. Because skin cancer incidence is increased in
patients with chronic GVHD, vigilant monitoring is necessary
so that early malignancies and premalignancies can be
detected early and treated appropriately.
Measures to Prevent the Development or Exacerbation of
GVHD
Environmental ultraviolet radiation can cause exacerba-
tion of cutaneous GVHD [5]. Photoprotection includes pro-
tective clothing, sun avoidance, physical sunblocks, and
sunscreens. Topically applied agents should protect against
both ultraviolet A (UVA) and ultraviolet B (UVB). Micronized
zinc, micronized titanium dioxide, mexoryl SX, or Parsol
1789 (avobenzone; DSM, Basel, Switzerland) are useful ad-
ditives to ensure adequate UVA protection. Laundry rinse
cycle additives can enhance the ultraviolet barrier function of
clothing.
Avoidance of Photosensitizing Agents
Several commonly prescribed medications have been
associated with phototoxic drug eruptions that typically
appear like severe sunburn, often associated with skin
burning and/or pruritus. This list of such medications is
extensive but voriconazole deserves special mention because
of its particular dual association with phototoxicity and
increased risk of squamous cell carcinoma [6].
Topical Care and Therapies for Intact Skin
Most patients with extensive rash will require systemic
therapy, a topic beyond the scope of this review.
Regular lubrication of dry but intact skin with emollients
may decrease pruritus and maintain skin integrity. Oint-
ments and creams are better skin softeners than lotions and
are less likely to sting when applied to erythematous skin.
Moisturizers that contain 3% to 10% urea or glycerol are
particularly efﬁcacious for increasing skin hydration, but
urea products can be more irritating to inﬂamed skin or in
infants.
Topical steroids and emollients can improve cutaneous
chronic GVHD, particularly nonsclerotic skin lesions without
erosions or ulcerations (lichen-planuselike or papulosqu-
amous plaques). Long-term use of topical steroids may be
complicated by local skin atrophy and development of striae.
1. General guidelines regarding topical steroid recom-
mendations for skin GVHD:
a. From the neck down: treatment should begin with
mid-strength topical steroids (eg, triamcinolone
0.1% cream or ointment). In unresponsive cases,
short-term occlusion of mid-strength steroids
with damp towels (“wet wraps”) increases skin
hydration and steroid penetration. When this is
impractical, higher potency steroids (eg,
Table 1
Summary of Ancillary Therapy and Supportive Care Interventions
Organ System Organ-Speciﬁc Intervention*
Prevention Treatment
Skin and appendages Photoprotection e sun avoidance and physical sunblocks
(eg, protective clothing, UVA, and UVB sunscreens).
Avoidance of photosensitizing agents (eg, voriconazole).
Surveillance for malignancy [2,3].
For intact skin e topical emollients including urea
containing products, corticosteroids, antipruritic agents,
and others (eg, PUVA or narrow band UVB, calcineurin
inhibitors).
For erosions/ulcerations e microbiologic cultures, topical
antimicrobials, protective ﬁlms or other dressings,
debridement, hyperbaric oxygen, wound care specialist
consultation.
Mouth and oral cavity Maintain good oral/dental hygiene. Routine dental cleaning
and radiographs. Surveillance for infection and malignancy.
Nutritional counseling, if needed.
Topical high and ultra-high potency corticosteroids and
topical calcineurin inhibitors. Topical analgesics. Therapy
for oral dryness (eg, salivary stimulants, sialogogues) and
for prevention of related complications (ie, dental decay).
Eyes Photoprotection. Surveillance for infection, cataract
formation, and increased intraocular pressure.
Artiﬁcial tears, ocular ointments, topical corticosteroids or
cyclosporine, punctal occlusion, humidiﬁed environment,
occlusive eye wear, moisture chamber eyeglasses,
cevimeline, pilocarpine, gas-permeable scleral contact lens,
autologous serum, microbiologic cultures, topical
antimicrobials, doxycycline.
Vulva and vagina Surveillance for estrogen deﬁciency, infection (HSV, HPV,
yeast, bacteria) and malignancy [3].
Water-based or silicone lubricants, topical estrogens,
topical corticosteroids or calcineurin inhibitors, dilators or
vibrators, surgery for extensive synechiae or obliteration,
early gynecology consultation. Avoid glycerin, paraben,
fragrance, and other additive products,
Gastrointestinal tract and liver Surveillance for infection (viral, bacterial, fungal, parasites) Rule out other potential etiologies. Dietary modiﬁcation,
enzyme supplementation for pancreatic insufﬁciency, bile
salt resins, gastroesophageal reﬂux management,
esophageal dilatation, ursodeoxycholic acid, topical
glucocorticoids, limitation of ethanol intake, avoidance of
hepatotoxins.
Lungs Surveillance for infection (Pneumocystis jiroveci, viral,
fungal, bacterial).
Rule out other potential etiologies (eg, infection,
gastroesophageal reﬂux). Inhaled corticosteroids,
bronchodilators, supplementary oxygen, pulmonary
rehabilitation. Consideration of lung transplantation in
appropriate candidates.
Hematopoietic Surveillance for infection (CMV, parvovirus) Rule out other potential etiologies (eg, drug toxicity,
infection). Hematopoietic growth factors, immunoglobulin
for immune cytopenias
Neurologic Calcineurin drug level monitoring. Seizure prophylaxis as
indicated, including blood pressure control, electrolyte
replacement, anticonvulsants. EMG monitoring and staging
in symptomatic patients takingmedications known to cause
neuropathy. Close monitoring of distal extremities for
wounds in insensate patients.
Occupational and physical therapy to prevent falls and
improve function, treatment of neuropathic syndromes
with tricyclic antidepressants, SSRI, or anticonvulsants [4].
Orthotics and assistive devices (canes andwalkers). Bracing,
splinting or surgical release for entrapment neuropathies.
Immunologic and
infectious diseases
Immunizations and prophylaxis against Pneumocystis
jirovecii, VZV, and encapsulated bacteria based on CDC
guidelines. Consider immunoglobulin replacement based
on levels and recurrent infections. Surveillance for infection
(viral, bacterial, fungal, atypical).
Organism-speciﬁc antimicrobial agents. Empiric parenteral
broad-spectrum antibacterial coverage for fever.
Musculoskeletal Surveillance for decreased ROM, bone densitometry,
calcium levels and 25-OH vitamin D. Physical therapy,
calcium, vitamin D, and bisphosphonates. Flexion-extension
x-rays to look for instability.
Physical therapy, bisphosphonates for osteopenia, and
osteoporosis. Spinal orthosis for instability and/or
intractable pain. Walking program, resistance training, core
strengthening.
SSRI indicates selective serotonin reuptake inhibitors; CDC, Centers for Disease Control.
* In general, close serial monitoring of all organ systems is recommended to promote early detection and intervention directed toward reversing or preventing
progression of chronic GVHDmanifestations and treatment-associated toxicities. Ancillary and supportive care therapies are commonly employed in addition to
systemic GVHD treatment, although in some cases their use may circumvent the need for systemic treatment or allow doses of systemic agents to be reduced.
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helpful. The most potent topical steroids (eg, clo-
betasol dipropionate 0.05%, halobetasol propio-
nate 0.05%) should not be used under occlusion.
The use of wet wraps and high-potency steroids
should be limited to less than 14 consecutive days,
if possible.
b. Face, axillae, and groin: lower potency steroids
(hydrocortisone 1% to 2.5%, desonide 0.05%) are
preferable for long-term use.
c. Emollients: these may be used after the application
of steroids. Emollients are occlusive and may in-
crease the potency of steroids.2. Antipruritics: Although pruritus related to GVHD
generally responds to immunosuppressive therapy,
other adjuvant treatments may be useful.
a. Topical: hydrocortisone/pramoxine or menthol-
based creams/lotions.
b. Systemic: antihistamines (eg, diphenhydramine,
hydroxyzine, ranitidine) may help, but severe pru-
ritus rarely responds to standard dosing. Refractory
symptoms may beneﬁt from the addition of
gabapentin.
3. Others interventions:
a. Psolaren with UVA [7-9] or UVA1 (340 to 400
nm) [10], UVB [11], or narrow-band UVB (311 to
Table 2
Summary of Monitoring Recommendations*
Parameter Minimum Frequency (mo)
During Systemic
Immunosuppressive Therapy
Interval history with symptom assessment (including psychosocial symptoms) and medication review 3
Physical examination (by healthcare provider)
General 3
Photographic ROM 3-6
Skin surveillance for secondary malignancy 6-12
Weight:
Adults 3
Children 1-3
Height:
Adults 12
Children 3-6
Nutritional assessmenty
Adults 3-6
Children 1-6
Tanner score (children and adolescents) 6-12
Developmental assessment (children and adolescents) 3-6
Laboratory monitoring
Complete blood counts with differential 3
Chemistry panel including renal and liver function tests 3
Therapeutic drug monitoring 3
IgG level (until normal and independent of replacement) 1-3z
Lipid proﬁle (during treatment with corticosteroids or sirolimus). 6
Iron indices (if red cell transfusions are required or if iron overload has been documented previously) 6-12
Pulmonary function tests (PFT) 3-6
Endocrine function evaluation, eg, thyroid function tests, bone densitometry (if an abnormal result might
change clinical management), calcium levels, 25-OH vitamin D
12
Subspecialty evaluations
Ophthalmology 3-12
Dental assessment and oral cancer surveillance, including soft and hard tissues examination (radiographs as indicated);
culture, biopsy or photographs of lesions (as clinically indicated); and professional dental hygiene.
6
Dermatology with assessment of extent and type of skin involvement, biopsy, or photographs (as clinically indicated). 12*
Gynecology for vulvovaginal involvement (as clinically indicated). 3-12
Physiotherapy with assessment of ROM (if joint limitation is present). 3-12
Neuropsychological testing (as clinically indicated). 12
* All organ systems should be monitored at least annually and after immunosuppressive therapy is completed during extended survivorship [1,2]. The scope
and frequency of monitoring should be individualized as clinically indicated. More frequent monitoring is strongly advised for those with active GVHD,
especially during high-risk periods (eg, treatment taper or escalation).
y Could be screened by health care provider and referred to nutritionist, if indicated.
z Context dependent because post-transplantation immunoglobulin replacement during chronic GVHD therapy is not routine after the ﬁrst post-
transplantation year except when there are recurrent sinopulmonary infections or HCT for underlying primary immunodeﬁciency disease. See Table 11.
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rosis is not present. Phototherapy may be
administered 2 to 3 times per week by derma-
tologists. Cautionary note: phototherapy is asso-
ciated with an increased risk of phototoxicity and
skin cancer.
b. Topical calcineurin inhibitors (eg, tacrolimus,
pimecrolimus) have been reported to improve ery-
thema and pruritus [13,14].Topical Care for Nonintact Skin
When appropriate, superﬁcial or deep tissue culture
should be obtained to test for bacterial, viral, fungal, or
mycobacterial infection in eroded, ulcerated, or suspicious
skin lesions. The differential diagnosis for noninfectious skin
lesions includes vasculitis, recurrent malignancy, GVHD, hy-
persensitivity or drug reactions, dermatitis, and primary skin
cancer. The general recommendations on wound care do not
differ from those for patients without chronic GVHD.
For speciﬁc dispensing information, please see
Supplement 2.
MOUTH AND ORAL CAVITY
Chronic GVHD can affect the oral cavity through lichen
planuselike involvement of the mucosa, salivary glandinvolvement with subsequent hypofunction and xerostomia,
and sclerotic involvement of the oral mucosa and sur-
rounding skin tissues. Oral chronic GVHD can cause pain,
sensitivity to various foods and beverages, taste impairment,
dryness, dental caries, and decreased ROM. Infections
including candidiasis and recrudescent herpes simplex virus
(HSV) should be ruled out before initiating any form of
therapy. When clinically indicated, viral and bacterial
cultures, viral PCR, or biopsies should be performed. Drug-
related conditions, such as sirolimus-associated aphthous-
like ulcerations and calcineurin inhibitoreassociated
ﬁbrovascular ulcerative lesions, must be considered.
Topical treatment may provide greater local beneﬁts than
systemic therapy alone (Table 4). When the oral cavity is the
only site of chronic GVHD activity, and evenwhen severe (eg,
extensive ulcerations), intensive ancillary treatment might
sufﬁce to control the disease in the absence of systemic
therapy.
All patients with oral chronic GVHD should be informed
about their higher risk for developing oral squamous cell
carcinoma and undergo annual screening by examination. In
particular, patients with persistent or new changes in the
oral mucosal color or texture or a growth should be evalu-
ated for second primary cancer to avoid misdiagnosis as
chronic GVHD. At the clinician’s discretion testing of the
Table 4
Ancillary Therapy and Supportive Care Recommendations for Mouth and Oral Tissues
Indication, Preparation*, Active agent, Concentration Rating
Lichenoid-related symptoms/ulcers and erosions Rinse Clobetasol 0.5 mg/mL (0.05%) AIa
Budesonide 0.3 mg/mL (0.03%) BIIa
Dexamethasone 0.1 mg/mL (0.01%) AIII
Triamcinolone 1 mg/mL (0.1%) AIII
Tacrolimus 0.1 mg/mL (0.01%) BIIa
Prednisolone 3 mg/mL (0.03%) BIII
Clobetasol:tacrolimus 1:1 Not speciﬁed CIII
Gel, paste, ointment Clobetasol gel 0.05% AIa
Tacrolimus ointment 0.1% BIIa
Fluocinonide gel 0.05% BIII
Intralesional injection Triamcinolone 40 mg/mL, .5 mL/cm2 CIIb
Mucosal pain Rinse Lidocaine 2% BIII
Kaolinite pectin-diphenhydramine-
lidocaine 1:1:1
Not speciﬁed BIII
Not applicable CO2 laser for pain relief [30] Not applicable CIIIy
Dry mouth Gel, toothpaste Fluoride Per manufacturer AIb
Rinse Water sipping Per need AIII
Gum, candy Salivary stimulants Per need AIII
Tablets Pilocarpine 5-10 mg  3-4/d BIIa
Cevimeline 15-30 mg  3/d BIII
Gastric reﬂux Tablets Proton pump inhibitor,
antireﬂux measures
CIII
PEDIATRIC CONSIDERATIONS
Behavioral: Children often don’t communicate symptoms of impaired speech, oral dryness or sensitivities, taste alteration, and dysphagia; reduced oral
intake and increased drinking during eating or at night may be presenting symptoms. Speciﬁc approaches to help parents assist children with oral topical
therapies may improve compliance.
Prevention of caries: Bottle drinking should not be used as a paciﬁer for small children and cup drinking should be introduced as early as possible. Counsel
the avoidance of reﬁned carbohydrates including juices and soft drinks.
Developmental: Fibrosis and limited mouth opening may contribute to the disruption of craniofacial growth.
Pharmacologic considerations: While oral mucosal chronic GVHD generally responds well to topical steroids or calcineurin inhibitors, these agents may
produce clinically relevant systemic drug levels in infants and small children. Viscous lidocaine may reduce the gag reﬂex, compromise swallowing and
should be used with caution. Sialogogue use has been limited in children and dosing is not established.
Orthodontic: Fixed braces should only be used after healing of acute inﬂammation. Speciﬁc guidelines for optimal force and pace of orthodontic
management in chronic GVHD remain undeﬁned.
* The selection of a localized or generalized treatment depends on the extent of oral chronic GVHD.
y Optional at centers experienced in the use of this therapy as it currently has limited availability.
Table 3
Ancillary Therapy and Supportive Care Recommendations for Skin GVHD
Type of Intervention Recommendation Rating
Preventive measures
Photoprotection: UVA and UVB blockade including:
Avoidance of sun exposure (especially between 10:00 am and 4:00 pm) AIII
Use of sunscreens (>SPF 20 with broad-spectrum UVA and UVB protection) AIII
Protective clothing AIII
Avoidance of photosensitizing agents AIII
Treatment
Intact skin
Symptomatic treatment with emollients and antipruritic agents AIII
Topical corticosteroids CIIb
Light therapy (PUVA, UVA1, UVB, narrow-band UVB) CIIa
Topical calcineurin inhibitors (pimecrolimus, tacrolimus) CIIa
Sclerotic manifestations with joint stiffness or contractures
Deep muscle/fascial massage (Heller works) to improve ROM CIII
Stretching exercises to improve ROM BIII
Erosions and ulcerations
Topical or oral antimicrobials BIII
Wound dressings and debridement CIII
Control of edema BIII
PEDIATRIC CONSIDERATIONS
Systemic side effects of topical steroids and topical calcineurin inhibitors may occur more frequently in young children because of the larger
skin surface area to body weight ratio.
Although the least potent topical steroids (1% to 2.5% hydrocortisone) are safe, middle to upper mid-strength topical steroids should generally be
used sparingly, and on limited areas, for no more than 3 to 4 wk.
Topical steroids under occlusive dressings are not recommended.
The use of potent or super-potent steroids on the face, or at any site in infants <1 yr of age, is not recommended.
Avoid urea or menthol containing products in young children because they may cause skin irritation.
SPF indicates sun protective factor; PUVA, photochemotherapy.
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serotypes may be added. Atypical persistent oral lesions
should be considered for a biopsy periodically to rule out
progression to malignancy, especially if dysplasia was
previously identiﬁed histopathologically. The response to
high-potency topical steroids may assist in differentiating
between oral lesions attributed to chronic GVHD and cancer.
However, additional differential diagnoses that may not
respond to topical steroids should be considered (eg,
hyperplastic candidiasis, frictional keratosis).
Oral Mucosal, Gingival, and Lip Chronic GVHD
The mainstay of ancillary therapy for symptomatic oral
mucosal or erythematous or ulcerative disease is the appli-
cation of high-potency corticosteroid preparations, although
evidence to guide the choice of speciﬁc agents is limited
(Table 4) [15-17]. Solutions are used mainly when manifes-
tations are generalized, whereas gels, creams, and ointments
are used for localized lesions, with gels generally preferable
due to their hydrophilic properties. Gels, creams, and oint-
ments may be applied locally with a ﬁnger or applied to
gauze, leaving the gauze in place against the lesion for 10 to
15 minutes before removing. It is important to educate pa-
tients on how to use steroid solution formulations. Alterna-
tive noncorticosteroid rinse formulations of tacrolimus or
cyclosporine may also be effective. Various topical prepara-
tions may be used in combinations (eg, a corticosteroid and
calcineurin inhibitor). The need for and intensity of these
topical therapies are driven primarily by patient symptoms
or presence of ulcers to re-establish integrity of the mucosal
barrier. The application of topical calcineurin inhibitors is an
alternative to locally applied corticosteroids [18,19]. Long-
term use of topical steroids has been associated with
atrophy of the lip vermillion but not of the oral mucosa.
Therefore, treatment of the lips with topical tacrolimus 0.1%
minimizes the risk of this adverse event. Intralesional in-
jections of triamcinolone steroids have been used success-
fully in patients with discrete symptomatic ulcerative lesions
that have not responded adequately to topical therapy [20].
All patients should be counseled about the relatively
frequent side effect of oral candidiasis and the systemic ef-
fects that can result from long-term use of topical therapy
with highly potent steroids. If candidiasis occurs, antifungal
prophylaxis strategies are effective with continued ongoing
topical steroid therapy.
Patients may need to avoid acidic, spicy, strongly ﬂavored,
and rough or crunchy foods and drinks because of sensitivity
and discomfort. If toothpaste causes oral burning, patients
should be instructed to use a children’s toothpaste. Topical
analgesia is helpful when symptomatic mucosal GVHD im-
pairs nutrition or communication. Viscous lidocaine may
provide some relief. In situations when topical immuno-
suppressive therapy causes localized burning discomfort,
addition of a small amount of viscous lidocaine can be
effective in making the rinse more tolerable, although
infrequent adverse events have been associated with the use
of lidocaine rinses. It is worth remembering that reﬂux of
acidic gastric contents in the context of inadequate salivary
bicarbonate may contribute to oral mucosal symptoms;
proton pump inhibitors and other antireﬂux measures might
be helpful when symptoms of heartburn are present.
Salivary Gland Chronic GVHD
Patients with salivary gland involvement most frequently
report dry mouth and present with signs of mucoid, viscoussaliva, reduced or absence of moist ﬁlm over the mucosal
surfaces, absent ﬂoor of mouth pooling, accumulation of soft
debris, and erythematous mucosal surfaces [21-23]. They
may also develop mucoceles, which are recognized as
generally painless but “annoying” blisters mostly on the
palate and inside the lower lip [24,25]. Patients with salivary
gland involvement may be at increased risk for developing
dental caries, in particular along the gum line and contact
areas. Even without use of intraoral topical steroids, patients
with salivary gland chronic GVHD may develop recurrent
candidiasis.
Ancillary care for dry mouth may include frequent water
sipping, the use of gustatory and mechanical saliva stimu-
lants (sugar-free gum and candy), oral moisturizing agents,
and saliva substitutes. The milder ﬂavored toothpastes
marketed for children are often better tolerated. Caries can
be prevented by home ﬂuoride treatments before sleep. Even
in patients without subjective oral dryness, mild salivary
gland dysfunction can increase the risk of tooth decay, and
topical ﬂuoride should be considered as a decay prevention
strategy [23,26]. If possible, avoidance of xerogenic medica-
tions such as tricyclic antidepressants, selective serotonin
reuptake inhibitors, antihistamines, and opioids may help
alleviate symptoms of dry mouth. Sialogogue therapy with
cholinergic agonists (cevimeline, pilocarpine) may produce a
signiﬁcant enhancement of salivary secretion and may be
offered in the absence of contraindications (eg, glaucoma,
heart disease, or obstructive pulmonary disease) [27,28].Sclerotic Manifestations of Oral Chronic GVHD
Topical therapy alone is insufﬁcient for treating sclerosis
of the perioral skin and surrounding tissues caused by
chronic GVHD. In this situation, systemic treatment is
required; however, the sclerosis is typically quite extensive
once perioral skin is affected. In cases of focal intraoral
mucosal sclerosis, typically affecting the posterior buccal
mucosa, adjunctive intralesional steroid injections may be
helpful, but long-term therapy is often required to maintain
the response. Stretching exercises with or without the use of
a physical therapy device to increase ROM of the mouth may
be helpful.Routine Dental Treatment
Patients with chronic GVHD should receive routine dental
care, including regularly scheduled professional dental
cleanings, and ﬂuoride applications. The necessity for anti-
biotic prophylaxis in patients with chronic GVHD remains
controversial. However, some centers follow The American
Heart Association’s protocol for prevention of bacterial
endocarditis [27]. Extended antibiotic therapy should be
determined by the transplantation physician based on the
dental disease, the type of treatment, and the patient’s risk
for infection.
Patients with chronic GVHD who are currently or have
previously been treated with antiresorptive therapy (eg,
bisphosphonates, denosumab) are at risk for developing
medication-related osteonecrosis of the jaw [29]. Similar to
dental screening before HCT, dental consultation and
implementation of appropriate dental and oral hygiene
measures should be initiated before antiresorptive therapy.
For speciﬁc dispensing information, please see
Supplement 3.
Table 5
Ancillary Therapy and Supportive Care Recommendations for Eye GVHD
Therapy Indication Rating
Topical Mild*
AT, preservative free AIb
Viscous ointment at bedtime/viscous tears during the day BIb
Moderate/severe*
Cyclosporine eye drops CIb
Topical steroid drops BIIIa
Lacriserts (Valeant Pharmaceuticals) for patients that use AT more frequently than hourly CIb
Autologous serum eye drops (limited availability) CIb/CIIa
Oral Moderate/severe*
Cevimeline CIb
Pilocarpine CIb
Surgical Moderate/severe*
Punctal occlusion (temporary or permanent occlusion, using silicone plugs or thermal cautery) BIb/IIa
Superﬁcial debridement of ﬁlamentary keratitis CIII
Partial tarsorrhaphy CIIb
Moderate/severe*
Eye wear/environmental strategy Occlusive eye wear (www.dryeyepain.com; BIII
www.panoptx.com) CIII
Lid care/warm compress/humidiﬁed environment CIII
Bandage contact lens (used with caution) CIII
Gas-permeable scleral lens CIIa
PEDIATRIC CONSIDERATIONS
Although severe ocular sicca is uncommon in children with chronic GVHD, measured tear production is reduced, and surveillance for keratoconjunctivitis
sicca is necessary.
Ocular sicca generally responds to ancillary measures in conjunction with systemic immunosuppression.
Experience is limited and dosing is not established for many of the topical and oral medications for ocular GVHD.
AT indicates artiﬁcial tears.
* Deﬁnitions of severity follow the Diagnosis and Scoring report [47].
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The clinical spectrum of chronic ocular GVHD includes
acute conjunctival inﬂammation, pseudomembranous and
cicatricial conjunctivitis, and, most frequently, keratocon-
junctivitis sicca (or KCS). KCS often accompanies chronic
GVHD activity in other organs and may be a prominent dis-
ease manifestation. Conversely, dry eyes may occasionally be
the only manifestation of chronic GVHD [31]. The diagnosis
of KCS is made by the presence of appropriate symptoms,
tear production averaging  5 mm (Schirmer’s test), and
clinical signs of keratitis. Although ocular symptoms and
external examination can be ascertained from a clinic visit, a
slit lamp examination by an ophthalmologist is generally
required to make the diagnosis of KCS. In all cases, infectious
keratitis must be ruled out. Most ancillary treatment for
ocular chronic GVHD is aimed at relief of dry eyes (Table 5).
When the sole manifestations of chronic GVHD are ocular,
systemic immunosuppressive therapy may need to be initi-
ated (or resumed) when topical and other local measures are
insufﬁcient to control inﬂammation and symptoms.
Symptoms include burning, irritation, pain, foreign body
sensation, blurred vision, photophobia, and paradoxically,
excessive tearing [32]. Other causes of dry eyes must be
considered, such as medications with anticholinergic side
effects (antihypertensives, antidepressants, psychotropics,
antihistamines, decongestants) and previous treatments
(such as total body irradiation, chemotherapy, history of
autologous HCT).
Aqueous tear deﬁciency/lacrimal gland dysfunction may
ﬂuctuate during systemic GVHD. Although systemic immu-
nosuppressive therapies for chronic GVHD generally do not
lead to improvement in the Schirmer scores, especially in
cases of longstanding lacrimal gland dysfunction, they can
improve overall symptoms of ocular GVHD.
If possible, an ophthalmologist who is knowledgeable
about GVHD should be involved to coordinate care in amultidisciplinary fashion. Ancillary and supportive care for
the eye focuses on increasing ocular surface moisture (by
lubrication and decreasing tear evaporation and tear
drainage from the surface of the eye) and on decreasing
ocular surface inﬂammation.
Decreasing Ocular Surface Inﬂammation
To decrease ocular surface inﬂammation, judicious use of
topical steroids may be necessary. In general, this type of
treatment should be reserved for the control of ocular GVHD
exacerbation when systemic immunosuppression is being
tapered [33]. Topical steroids have been used for cicatricial
conjunctivitis in limited case series [34]. Pulsed topical ste-
roids should be carefully supervised by an ophthalmologist,
as steroid-related complications include increased intraoc-
ular pressure, cataract formation, and silent infectious
keratitis. Topical cyclosporine can be prescribed to control
immune responses at the ocular surface [35]. The beneﬁt of
topical cyclosporine on tear function in GVHD has not been
documented, but this type of treatment increases Schirmer
scores and decreases surface apoptosis in patients with other
dry eye conditions. Ocular surface inﬂammation may also be
improved with autologous serum, but this treatment is
available in only a limited number of centers [36,37].
Lubrication
For lubrication, the range of adjunctive measures includes
the use of preservative-free artiﬁcial tears to coat the ocular
surface, thereby minimizing superﬁcial punctuate keratop-
athy (dry spots on the cornea), reducing the ocular symp-
toms, and improving the quality of vision. Because patients
may tolerate certain formulations better than others, they
should be encouraged to test different brands to identify that
which provides the most beneﬁt.
For patients whomay require application of artiﬁcial tears
more than once every hour, the use of slowly dissolving 5 mg
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convenient [38]. Lacriserts (Valeant Pharmaceuticals,
Lakewood, NJ) are available by prescription and are inserted
once or twice daily into the inferior cul-de-sac of the eye but
may produce a constant foreign body sensation. Oral medi-
cations may be used to increase lubrication by stimulating
aqueous tear ﬂowwith selective muscarinic agonists, such as
cevimeline [39] or pilocarpine [40]. These have been shown
to improve sicca symptoms in patients with Sjogren’s syn-
drome, but drug interactions and toxicities must be reviewed
because contraindications include glaucoma, heart disease,
and asthma.
Control of Drainage
To decrease drainage from the surface of the eye, tem-
porary or permanent occlusion of the tear duct punctae may
provide additional beneﬁt for patients with severe ocular
sicca syndrome (<5 mm tear wetting) [41-43]. Permanent
punctal occlusion (via thermal cauterization) may be
necessary, as the silicone plugs used for temporary occlusion
fall out repeatedly. Repeated thermal cautery may be needed
if punctae reopen.
Control of Evaporation
Scleral lenses are beneﬁcial in severe cases and are
becoming more widely available [44-46]. These gas-
permeable lenses are larger in diameter than regular con-
tact lenses. By ﬁtting on the sclera, they can often be worn by
patients who are otherwise contact lens intolerant. In situ,
scleral lenses continuously bath the cornea via a ﬂuid
reservoir of saline and/or artiﬁcial tears, which helps reju-
venate ocular surfaces. This ﬂuid reservoir cushion covers
distorted corneal surfaces, improves vision, and reduces pain
and photosensitivity.
For speciﬁc dispensing information, please see
Supplement 4.
GENITALIA
General Hygiene, Routine Surveillance, and Vulvovaginal
Atrophy
General hygiene, routine gynecologic evaluations, as well
as management of vulvar and vaginal atrophy are important
to integrated care but are beyond the scope of this article.
(See also Supplement 5).
Vulva and Vaginal Mucosa
The incidence of vulvovaginal chronic GVHD ranges be-
tween 20% and 50% based on gynecological surveillance
evaluations up to 2 years after transplantation, with a higher
risk in recipients of a peripheral blood graft [48-50]. The
diagnosis of vulvovaginal GVHD relies on symptoms and
physical ﬁndings. Histological conﬁrmation is strongly rec-
ommended in the absence of diagnostic manifestations of
chronic GVHD in other organs. Estrogen deﬁciency and in-
fections (HPV, HSV, yeast, bacteria, or other recognized gy-
necological pathogens) must be ruled out at the time of
initial diagnosis and periodically during management of
vulvar or vaginal GVHD.
Chronic GVHD of the vulva and vagina presents with ab-
normalities of the mucosa or manifestations of sclerotic
changes. Symptoms may include dysuria, dryness, tender-
ness to touch, and dyspareunia. Mild chronic GVHD of the
vulva may occasionally be asymptomatic and detected only
by examination. Mild to very active vaginal chronic GVHD
can be asymptomatic. Physical ﬁndings of the vulva includeerythematous patches (mucositis), retiform leucokeratosis
(lichen-planuselike lesions), vestibular tenderness, aggluti-
nation of vulvar structures with thin adhesions or dense
ﬁbrosis between the clitoris and prepuce, or across the
interlabial sulcus, and less often, ulcers. Vaginal ﬁndings
include mucositis, ulcers, a yellow or green discharge, phi-
mosis, and dense ﬁbrotic changes that commonly involve the
cervival-vaginal sulcus. Sclerosis of vulvar and vaginal tissues
can lead to narrowing of the introitus, shortening, and even
complete obliteration of the vaginal canal. Adhesions and
ﬁbrosis that involve the upper vagina or cervix may lead to
hematometra. Although most patients with vulvar or vaginal
GVHD have involvement of the mouth or other sites, vulvo-
vaginal manifestations may sometimes be the only sign of
chronic GVHD [48,49,51].
Post-HCT females of appropriate age, and especially those
who are symptomatic, should be evaluated and followed by a
gynecologist with experience in GVHD, and if not available,
by practitioners with experience in non-neoplastic inﬂam-
matory diseases of the genital tissues, such as lichen planus.
Vulvovaginal GVHD
When the vulvovaginal region represents the only clinical
manifestation of chronic GVHD activity, topical immuno-
suppressive agents might constitute an adequate primary
therapy for controlling mild clinical manifestations (Table 6).
Application of ultra-high potency corticosteroid is the
mainstay of therapy, whereas topical calcineurin ointments
also have efﬁcacy [48,49,51-55]. The anti-inﬂammatory
antibiotic clindamycin has been used successfully as an
intravaginal therapy, often applied together with cortico-
steroids [56]. Patients may develop candidiasis or experience
recurrence of HSV or HPV during immunosuppressive ther-
apy and must be counseled to monitor for symptoms.
Sclerotic features of vaginal GVHD should be treated
aggressively with topical corticosteroids and dilators. Surgi-
cal lysis with or without vaginal reconstruction is necessary
for patients with extensive synechiae and complete obliter-
ation of the vaginal canal. Topical treatment with calcineurin
inhibitors has been used successfully to avoid surgery in
some cases. These agents have also been used post-
operatively with resumption of vaginal intercourse [53].
Penis and Foreskin
Only a few cases of male genital chronic GVHD have been
reported, including lichenoid genital lesions on the foreskin
or glans penis, phimosis, lichen sclerosis, and contracture
secondary to Peyronie’s disease [57]. Routine assessment as
part of the history and physical is essential for early detection
of this rare but treatable manifestation of GVHD.
GASTROINTESTINAL TRACT AND LIVER
Gastrointestinal manifestations occur frequently in pa-
tients with chronic GVHD. These include dysphagia, odyno-
phagia, heartburn, anorexia, nausea, vomiting, abdominal
pain, diarrhea, weight loss, malnutrition, and jaundice. Each
of these symptoms has a speciﬁc differential diagnosis that
includes chronic GVHD, protracted acute GVHD, infection,
biliary stone disease, medication side effects, and ﬁbrotic
complications of a previous injury (eg, intestinal strictures
and hepatic ﬁbrosis). The diagnosis of 1 cause of symptoms
does not preclude the presence of other causes. Therefore, it
is important to conﬁrm the diagnosis of chronic GVHD before
beginning treatment [58,59].
Table 6
Ancillary Therapy and Supportive Care Recommendations for Vulvar and Vaginal GVHD
Type of Intervention Rating
Vulvar hygiene to minimize irritation
Avoid skin contact with chemical irritants (eg, soap and feminine wash products) and synthetic clothing BIII
Cleanse genital area with warm water, allow air circulation, and wipe front to back, use cotton underwear BIII
Sparing use of simple emollients to vulva (not vagina) BIII
Personal lubricants BIII
Vulvovaginal atrophy
Topical intravaginal or systemic estrogen  progestin therapy as indicated based on patient-speciﬁc considerations BIII
Topical therapy for vulvar GVHD
Clobetasol gel 0.05% (vagina) BIIa
Betamethasone dipropionate 0.05% ointment BIII
Tacrolimus ointment 0.1% (vulva) BIIb
Topical therapy for vaginal GVHD
Hydrocortisone (10%) in 2% clindamycin base (apply 5 g with vaginal applicator nightly) BIII
Clobetasol gel 0.05% applied twice daily BIIa
Betamethasone dipropionate augmented gel BIII
Tacrolimus vaginal suppositories 0.1% nightly (2 mg tacrolimus per 2 g suppository) BIIb
Surgical therapy
Surgical lysis with or without vaginal reconstruction followed by 6 mo of dilator therapy may be necessary for treatment of extensive
synechiae and complete obliteration of the vaginal canal.
BIII
PEDIATRIC CONSIDERATIONS
Vulvar or vaginal GVHD needs to be considered as soon as physical development has progressed beyond thelarche and into pubarche.
Vulvovaginal GVHD has been observed infrequently in prepubertal girls.
Evaluation by an adolescent gynecologic practitioner is recommended when a diagnosis of vulvovaginal GVHD is being considered.
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Lubrication can ease swallowing discomfort due to xero-
stomia. Other possible causes of odynophagia or dysphagia
include esophageal webs, rings, strictures, dysmotility, or
nonchronic GVHD diagnoses, such as pill esophagitis, infec-
tion, radiation esophagitis, and strictures caused by peptic
reﬂux. Endoscopy is usually needed to exclude or conﬁrm
these diagnoses. Esophageal dilation may be helpful in pa-
tients with documented webs or strictures, but this proce-
dure can cause perforation and should be performed by an
experienced gastroenterologist (Table 7).
Diarrhea
Patients presenting with acute diarrhea should have a
standard infectious screen depending on severity and
epidemiologic considerations (eg, enteric bacterial and viral
pathogens, Clostridium difﬁcile toxin, cytomegalovirus [CMV],
adenovirus). Protracted diarrhea during treatment with
immunosuppressive medications requires a broad search for
gut pathogens, including norovirus, rotavirus, astrovirus,
cryptosporidia, giardia lamblia, microsporidia, and others,
depending on geographic conditions. The differential diag-
nosis also includes noninfectious, causes such as intestinal
mucosal disease, pancreatic insufﬁciency, magnesium and
other medication side effects. Of note, CMV enteritis can be
present without CMV viremia. Pancreatic atrophy, anTable 7
Ancillary Therapy and Supportive Care Recommendations for GI/Liver GVHD
Type of Intervention Rating
Esophageal dilation for webs or stricture BIII
Dietary modiﬁcations for carbohydrate, fat malabsorption BIII
Pancreatic enzyme replacement for insufﬁciency BIIa
Ursodeoxycholic acid if cholestasis BIIa
Lactase tablets or lactase-containing dairy products BIII
Topical glucocorticoid formulations for late acute GVHD CIa
Bile acid binding resins if bile salt malabsorption
(eg, cholestyramine)
CIII
PEDIATRIC CONSIDERATIONS
No substantive differences.indication for enzyme supplementation, occurs rarely in
patients with prolonged chronic GVHD. Mycophenolate
mofetil may also cause enteritis with manifestations similar
to GVHD. Acute GVHD of the gastrointestinal tract may
beneﬁt from the addition of oral topical glucocorticoids.
Judicious use of loperamide or diphenoxylate for diarrhea,
nortriptyline or dicyclomine for symptoms of irritable bowel
syndrome, or pancreatic enzymes for fat malabsorption
symptoms can be considered in the right clinical
circumstances.
Abnormal Liver Tests
Liver disorders in patients with chronic GVHD may pre-
sent in several ways: abnormalities of blood tests (alanine
aminotransferase [ALT], alkaline phosphatase [AP], gamma-
glutamyl transpeptidase [GGT], bilirubins, iron/ferritin);
development of signs of portal hypertension and end-stage
liver disease; and abnormalities on hepatobiliary imaging
(ultrasound, computed tomography, magnetic resonance
imaging). Each presentation has a speciﬁc differential diag-
nosis and treatments depend on accurate diagnoses, which
in turn depend on a careful history, liver imaging, viral tests,
and in some patients, liver histology. Liver GVHD pre-
sentations may be hepatitic (elevated serum aspartate and
alanine aminotransferases, AST/ALT) and cholestatic. Signif-
icant ALT elevations and any degree of jaundice require
systemic treatment with immunosuppressive medications
and ursodeoxycholic acid if the cause is GVHD. Treatment of
iron overload is also indicated when present. Multiple causes
of liver dysfunction can be present simultaneously. Causes of
portal hypertension are investigated with cardiac, hepatic
vein, and liver imaging, along with liver elastography and
histology in some cases.
Management of liver GVHD with persistent cholestasis,
chronic viral hepatitis, iron overload, or end-stage liver dis-
ease is beyond the scope of this manuscript.
Weight Loss
Chronic GVHD is an important risk factor for low body
mass index and lean body mass [60], but the mechanisms
Table 8
Ancillary Therapy and Supportive Care Recommendations for Lung GVHD
Type of Intervention Rating
Inhaled corticosteroids and bronchodilators CIb
Fluticasone, azithromycin, montelukast CIII
Prophylactic IVIG DIa
Pulmonary rehabilitation CIII
Supplementary oxygen AIII
PEDIATRIC CONSIDERATIONS
Formal spirometry, lung volumes and diffusing capacity are not
measurable in children < 7 yr of age, but negative plethysmography
is an option.
Actual measured PFT values must be carefully considered in pediatric
patients, because predicted normal values vary with age, weight, and
height. Therefore, percent predicted values might spuriously show
serial decrease over time without substantive decline in absolute
values.
Table 9
Ancillary Therapy And Supportive Care Recommendations for the Hemato-
poietic System
Type of Intervention Rating
Growth factors (G-CSF, GM-CSF, erythropoietin) CIII
Immunoglobulin for cytopenias CIII
Eculizumab for thrombotic microangiopathy CIII
PEDIATRIC CONSIDERATIONS
No substantive differences.
G-CSF indicates granulocyte colonyestimulating factor; GM-CSF, gran-
ulocyte macrophage colonyestimulating factor.
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ryngeal and esophageal pathology. In addition, upper
gastrointestinal GVHD is frequently accompanied by anhe-
donia for food, anorexia, and satiety. Immunosuppressive
medications such as calcineurin inhibitors, mycophenolate
mofetil, azoles, and trimethoprim/sulfamethoxazole (TMP/
SMX) commonly cause nausea. Weight loss in patients with
extensive chronic GVHD may also be caused by increased
action of glucagon and norepinephrine, resulting in an in-
crease in resting energy expenditure and alterations in fat
and carbohydrate oxidation rates [61]. Nutritional support is
very important as around 30% of adults [62,63] and up to 40%
of children with chronic GVHD are malnourished [64]. The
input of a nutritionist can be very helpful in addressing
weight loss, as some patients will need total parenteral
nutrition or tube feedings. A multidisciplinary team
including a gastroenterologist, nutritionist, and oncologist
may help to ensure adequate nutrition.
For speciﬁc dispensing information, please see
Supplement 6.
LUNG
The currently recognized noninfectious pulmonary
manifestations of chronic GVHD are bronchiolitis obliterans
syndrome (BOS) and its earlier precursor, which is lesser
degrees of airﬂow obstruction [65]. Dyspnea, wheeze, or
cough occur frequently in chronic GVHD and clinical exam-
ination, pulmonary function tests (PFTs) [66-68], radiologic
studies, and bronchoalveolar lavage help to distinguish BOS
from other pulmonary diseases (eg, pulmonary thrombo-
embolism, cryptogenic-organizing pneumonia, radiation-
induced lung injury), extrapulmonary diseases (eg,
effusions, subcutaneous sclerosis), and lung infections. Air
trapping and bronchiectasis may result from advanced BOS,
infections, or both. Pneumothorax, pneumomediastinum, or
subcutaneous emphysema might cause respiratory deterio-
ration independently or may complicate BOS. Common dis-
eases that may contribute to lung function deterioration
(with or without BOS) should be investigated and treated,
including chronic postnasal drip, recurrent sinus infections,
or gastroesophageal reﬂux disease [65].
Because the prognosis of BOS remains poor, early diag-
nosis and treatment are considered essential. Limited data
are available to guide the frequency of post-transplantation
PFT monitoring in asymptomatic patients, those with
chronic GVHD, or those with established BOS. Because pa-
tients may have subclinical changes in pulmonary function
before a diagnosis of chronic GVHD or BOS has been made,
frequent monitoring of PFTs or at least limited spirometry
every 3 months is recommended for high-risk patients dur-
ing the ﬁrst 1 to 2 years by some experts [65,69,70], followed
by additional evaluations in the setting of unexplained irre-
versible decline of forced expiratory volume in 1 second
(FEV1) >10% [69]. More data are needed to further deﬁne the
role of bronchoscopy or chest imaging in monitoring pul-
monary complications after HCT, including new diagnostic
tools such as parametric response mapping [71].
In established BOS, small retrospective studies suggest a
beneﬁcial effect on symptoms, stabilization of FEV1 and
reduced systemic prednisone exposure, when inhaled cor-
ticosteroids are added either alone [72] or in combination
with bronchodilatators [73] or azithromycin and mon-
telukast [74] (Table 8). Combination therapywith ﬂuticasone,
azithromycin, and montelukast is tolerable and may beneﬁt
newly diagnosed BOS. Pulmonary rehabilitation programsmay be beneﬁcial in BOS [75], as has been shown in chronic
obstructive pulmonary disease. Standard 6-minute walk
tests [76] help to better characterize physical performance
and identify patients who need supplemental oxygen based
on having pulse oximeter oxygen saturation (SpO2) <87%
while breathing room air.
Respiratory infections may aggravate respiratory impair-
ment and should be treated urgently. Bronchoalveolar lavage
is highly recommended, as the only manifestation of a sig-
niﬁcant lung infection may be a decline in FEV1 or forced
vital capacity. Patient education for preventive measures
against transmission of respiratory infections and avoidance
of inhaled pulmonary toxins from cigarettes, marijuana, and
dust should be emphasized. Interventions pioneered in lung
transplantation and management of cystic ﬁbrosis, such as
inhaled amphotericin, tobramycin, and rotating antibiotics
have not been tested in chronic GVHD but might be
considered for individual patients with frequent repetitive
infections.
Lung transplantations have been performed in a small
number of patients for the treatment of severe BOS and re-
ports suggest the resulting BOS recurrence rates have been
low. Therefore, it is reasonable to discuss this option with a
thoracic transplantation specialist for HCT recipients whose
underlying malignancy is in remission or if transplantation
was done for non-malignant indications.
For speciﬁc dispensing information, please see
Supplement 7.
HEMATOPOIETIC SYSTEM
Cytopenias may be caused by stromal damage, graft fail-
ure, drug toxicity, infection, relapse of underlying disease,
CMV infection, hemolysis, the anemia of chronic disease, and
autoimmune processes, including GVHD [77-80]. Intrave-
nous immunoglobulin may be effective in certain cytopenias
Table 10
Ancillary Therapy and Supportive Care Recommendations for Neurologic
Syndromes of GVHD
Type of Intervention Rating
Neuropathies:
Tricyclic antidepressants (eg, amitriptyline) BIIb
SSRI (eg, citalopram) CIIb
Anticonvulsants (eg, gabapentin, pregabalin) BIb
Bracing/splinting [102] BIb
Surgical release BIb
Muscle cramps:
Baclofen CIII
Clonazepam or diazepam (in the evening or at bedtime) CIII
Cyclobenzoprine (short term use: 2-3 wk) CIII
Ropinirole (1-3 hours before bedtime) CIII
Quinine sulfate (FDA blackbox warning 11/2009) EIIb
Neuropathies/myopathies/CNS disease
Rehabilitation medicine (PM&R, PT/OT, orthotics) [103,104] CIII
Plasmapheresis for TTP BIIb
IVIG BIIb
PEDIATRIC CONSIDERATIONS
Drugs of the SSRI antidepressant class should generally be used under
expert supervision because of the increased risk of suicidal
tendencies associated with their use in children.
Gabapentin may be used with success for treating extremity
dysesthesias or muscle cramps but experience is very limited with
other agents for muscle cramps.
FDA indicates Food and Drug Administration; CNS, central nervous system;
PT, physical therapy; OT, occupational therapy; TTP, thrombotic thrombo-
cytopenic purpura.
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(Table 9). Growth factor use has not been formally evalu-
ated in chronic GVHD patients with persistent cytopenias.
Thrombocytopenia at the time of diagnosis of chronic GVHD
is associated with poor prognosis [81,82] but may also be
caused by autoantibodies that would respond to treatment
with steroids or rituximab. Eosinophilia can occur with
either acute or chronic GVHD [83,84]. In patients with
chronic GVHD, eosinophilia has been associated with
elevated serum levels of IL-5 [85] and can herald or represent
disease activity [86]. Emerging data suggest that the terminal
complement inhibitor eculizumab could have a role in the
treatment of HCT-associated thrombotic microangiopathy
[87,88].NEUROLOGIC SYSTEM
Chronic GVHD of the nervous system is rare but can
present as polyneuropathy, myositis and myasthenia [89].
Symptoms may include muscle weakness and wasting, pain,
burning, dysesthesias, and parasthesias. Less clearly associ-
ated with chronic GVHD are central nervous system mani-
festations, such as cerebral angiitis and vasculitis or
encephalitis-like disease [90,91]. In contrast, muscle
cramps are a relatively common symptom but not neces-
sarily directly attributable to chronic GVHD.Neuropathy and Myopathy
Painful neuropathy and myopathy can occur in patients
with chronic GVHD [89]. Consideration of chronic inﬂam-
matory demyelinating polyneuropathy may require cere-
brospinal ﬂuid examination, electromyography (EMG)
studies, and sural nerve biopsy if symptoms present without
other evidence of chronic GVHD [89,92]. EMG, including
nerve conduction studies, is also useful in measuring the
severity and progress of peripheral neuropathy. Neuropathic
pain can occur in a dermatomal distribution in the absence of
rash during the prodromal phase of varicella zoster virus(VZV) reactivation. Speciﬁc interventions for painful pe-
ripheral neuropathies may include the use of tricyclic anti-
depressants [93], selective serotonin reuptake inhibitors
[94], and anticonvulsants [95] (Table 10). Opioid analgesics
are poorly effective as a solitary approach for relieving
neuropathic pain, but they may provide some relief and can
be an important adjunct to treatment when other ap-
proaches provide inadequate relief [96]. Because of unto-
ward side effects, such as sedation, these medications may
need to be titrated up slowly, as tolerated by the patient,
until symptoms are adequately controlled. Rehabilitation
medicine consultation with physical and occupational ther-
apy should be considered for all patients who have a
decreased ability to perform activities of daily living or
impaired quality of life because of pain or muscle weakness.
Falls are more prevalent among patients with proximal
myopathy or those with distal weakness and poor proprio-
ception due to neuropathy; the latter may require orthotic
support [97]. Insensate distal extremities are also at risk for
skin breakdown and wound infection from trauma, even
mild, that goes unnoticed. Therefore, when distal sensory
loss is present, frequent skin checks are advised either by the
patient, a caregiver, or the medical team.
GVHD also places patients at risk for entrapment mono-
neuropathies due to sclerosis and associated contractures,
fasciitis, and decreased tissue coverage (muscle, adipose
tissue) over pressure-sensitive areas. Patients should be
monitored for symptoms of carpal tunnel syndrome, ulnar
neuropathy at the elbow, and peroneal neuropathy at the
ﬁbular head. EMG and nerve conduction studies can di-
agnose and grade the severity of these mononeuropathies.
Treatmentmay include bracing and splinting, off-loading the
affected area, or surgical release.
Exercise should be encouraged based on physician rec-
ommendations or through a cancer-trained group program
to maintain muscle strength. This requires strength training,
not only aerobics.Myasthenia Gravis and Polymyositis
Myasthenia gravis occurs rarely in chronic GVHD. The
diagnosis is suggested by the syndrome of ptosis, extraocular
muscle weakness, and proximal limb and facial weakness in
the presence of antiacetylcholine receptor antibodies [98].
Polymyositis can present with proximal muscle weakness
that is often painful and associated with an elevated serum
concentration of creatinine phosphokinase and aldolase [99].
Isolated polymyositis occurs rarely as the sole manifestation
of chronic GVHD and muscle biopsy may be required to
establish the diagnosis [100,101].Muscle Cramps
Skeletal muscle cramps of the extremities and severe
carpopedal spasms, with impairment of ﬁnemotor functions,
are often observed in patients with chronic GVHD. Generally,
conventional muscle relaxants and analgesics are ineffective.
It is important to exclude electrolyte disturbances, particu-
larly hypomagnesemia. Various interventions have been
tested (Table 10) but must be implemented in a way that
accounts for the speciﬁc situation in each individual; a
careful review of risks and beneﬁts is strongly advised.
For speciﬁc dispensing information, please see
Supplement 8.
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Infection is the most common cause of mortality in pa-
tients with chronic GVHD and infection prophylaxis requires
special emphasis. The immune defects in chronic GVHD are
broad, encompassing macrophage function, antibody pro-
duction, and T cell function. Prevention, early diagnosis, and
prompt treatment of infections are essential to the sup-
portive care of patients with chronic GVHD. Recommenda-
tions supported by published evidence are more often based
on results from studies with patients who had conditions
other than chronic GVHD. Comprehensive guidelines for the
prevention of opportunistic infections after HCT have been
published in collaboration by the Center for Disease Control,
the Infectious Disease Society of America, and the American
Society of Blood and Marrow Transplantation [105,106].
Antibacterial Prophylaxis
Patients with chronic GVHD are considered at risk for
infection with encapsulated bacteria, particularly Strepto-
coccus pneumoniae, but also Haemophilus inﬂuenzae and
Neisseria meningitides. Encapsulated organism prophylaxis
should be given to all patients with chronic GVHD while
systemic immunosuppressive treatment is being given
(Table 11). Optimal selection of prophylaxis considers local
patterns of pneumococcal resistance and individual allergies
or toxicities associated with available antibiotic choices that
include penicillin, cotrimoxazole, second-generation cepha-
losporins, quinolones, and azithromycin. None of these
strategies have been tested in randomized trials but histor-
ical data indicate that fulminant septic events can occur
without prophylaxis due to the profound immunosuppres-
sion. When pneumococcal resistance patterns permit, a daily
cotrimoxazole regimen can provide prophylaxis againstTable 11
Ancillary Therapy and Supportive Care Recommendations for Immunologic and In
Type of Intervention
Antibacterial prophylaxis
Antibiotic prophylaxis for encapsulated organisms:
Penicillin Vee-K (if supported by resistance patterns)
Alternatives: cotrimoxazole, second generation cephalosporins, quinolones
Pneumococcal vaccine
Hib vaccine
IVIG routinely after allogeneic HCT
IVIG in patients with severe hypogammaglobulinemia and repeated sinopulm
Antibiotic prophylaxis before dental extractions and other invasive procedure
Antifungal prophylaxis
Prophylaxis for Candida infection
Primary prophylaxis with agents with activity against mould if prednisone >0
Secondary prophylaxis with pathogen speciﬁc agent for prior history of mold
Pneumocystis jirovecii antibiotic prophylaxis
Antiviral prophylaxis
HSV prophylaxis
VZV prophylaxis
CMV prophylaxis in seropositive cord blood recipients during the ﬁrst year af
Inﬂuenza vaccination with killed vaccine
Early empirical treatment with oseltamivir during inﬂuenza outbreaks
PEDIATRIC CONSIDERATIONS
Children undergoing HCT have frequently missed routine childhood immunizati
indicated.
Heptavalent conjugated pneumococcal vaccine is recommended at 12 and 14 m
recommended that children between 2-5 yr of age receive one dose of the 23
conjugated vaccine.
Patients with primary immunodeﬁciency diseases (examples: severe combined im
chronic granulomatous disease), regardless of their serum immunoglobulin le
transplantation. Defects in T cell and B cell collaboration often exist such that
cell numbers are variably restored; mixed donor T and B cell chimerism may
specialize in HCT for PID typically advocate maintaining serum trough IgG lev
Hib indicates Haemophilus inﬂuenzae type b.Pneumocystis jirovecii pneumonia (PJP), pneumococcus, and
to some extent toxoplasmosis and nocardia.
Antibiotic prophylaxis before dental extractions and other
invasive procedures in patients with chronic GVHD has not
been studied and consensus on this subject has not been
reached (see also above under “Routine dental cleaning”).
Vaccinations
Although no studies have evaluated the degree of protec-
tion provided by vaccination against encapsulated organisms
in patients with chronic GVHD, expert consensus opinion
advocates their use beginning as early as 3 to 6 months after
transplantation, as the T celledependent conjugated vaccines
are more effective than the older polysaccharide vaccines and
the risk of adverse outcomeswith vaccination is low [105,106].
Nonetheless, some centers require an arbitrary numeric level
of immune reconstitution if vaccinations for pneumococcus,
H. inﬂuenzae type b, and N. meningitides are given before 1
year after transplantation (eg, serum IgG level > 400 mg/dL,
CD4 T cells > 200/mL, and CD19 B cells > 20/mL). Vaccination
with trivalent inﬂuenza vaccine but never the live attenuated
inﬂuenza vaccine is advised for all recipients who are at least 6
months out from HCT, and in the midst of an inﬂuenza
epidemic, as early as 4months after HCT. Inactivated inﬂuenza
vaccine is also recommended for all close contacts. No live
virus vaccine should be given, including the live attenuated
measles, mumps, rubella, varicella, and zoster vaccines.
Household contacts should not be given oral polio vaccine.
Intravenous Immunoglobulin
Universal administration of intravenous immunoglobulin
(IVIG) after HCT has not been shown to confer clinical beneﬁt
and should be avoided [107,108]. In patients withfectious Complications of Chronic GVHD
Recommendation Rating
BIIb
and azithromycin CIII
BIIb
BIIb
D
onary infections CIII
s CIII
CIII
.5-1 mg/kg/day AIa
CIII
AIb
D
CIa
ter transplantation CIIa
BIII
CIII
ons. Review of immunization history and patient-speciﬁc vaccination is
o after HCT for patients less than or equal to 5 yr of age. It is also
-valent pneumococcal vaccine 2 mo after the last dose of the heptavalent
munodeﬁciency disease, Wiskott Aldrich syndrome, IPEX syndrome, and
vels, have never completed a primary immunization series at the time of
serum immunoglobulins may be functionally defective. After transplant, B
also complicate restoration of functional immunoglobulins. Centers that
els of 600 to 800 mg/dL.
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administration of IVIG to maintain IgG levels above 400 mg/
dL has been associated with a reduced incidence of severe
bacterial infections [109-111]. IVIG may be considered for
patients who have recurrent sinopulmonary infections and
serum IgG levels < 400 mg/dL > 90 days after HCT. Some
experts recommendmonitoring IgG levels and administering
IVIG routinely in chronic GVHD, but there are no data
demonstrating that this approach improves outcomes.
Antifungal Prophylaxis
Invasive mold infections are a signiﬁcant risk for patients
with severe cell-mediated immunodeﬁciency caused by
chronic GVHD and its treatment. Although controversies
remain about the appropriate duration of therapy, dosing
and drug levels, drug interactions, and resistant break-
through infections, many centers prescribe primary pro-
phylaxis with posaconazole [112] or voriconazole for
patients considered at high-risk for invasive mold infections,
such as those with chronic GVHD treated with higher doses
of steroids (>0.5 to 1.0 mg/kg/day). Most centers also pre-
scribe secondary prophylaxis during systemic corticosteroid
therapy for chronic GVHD. Selection of an appropriate pro-
phylactic drug is based on the speciﬁc pathogen that caused
the previous invasive mold infection and the response to
antifungal therapy during that episode.
Pneumocystis Jirovecii Prophylaxis
PJP more than 6 months after HCT is strongly associated
with chronic GVHD. All patients should receive PJP prophy-
laxis during immunosuppressive treatment after allogeneic
HCT [106]. The optimal duration of continued prophylaxis
after stopping immunosuppression has not been deﬁned,
and practices vary widely among centers. The ﬁrst choice of
prophylaxis for PJP is trimethoprim-sulfamethoxazole. Al-
ternatives include dapsone, atovaquone, and aerosolized or
intravenous pentamidine, although pentamidine has
appeared inferior to other regimens [113].
Antiviral Prophylaxis
Approximately 30% to 60% of patients experience an
episode of zoster during the ﬁrst year after discontinuing
post-transplantation prophylaxis [114]. Some experts use
long-term antiviral prophylaxis to prevent recurrent HSV
and VZV infection among HCT recipients with severe, long-
term immunodeﬁciency [115-117], but current evidence
does not support routine administration of antiviralTable 12
Ancillary Therapy and Supportive Care Recommendations for Fasciitis, Contracture
Type of Intervention
Fasciitis/Contractures
Refer to PT for quantitative ROM measurements, to provide the patient with s
Evaluation of ROM at each clinic visit.
Daily stretching exercises at home
PT stretching 2-3 times a wk (severe impairment)
Surgical release
Steroid myopathy and deconditioning
Strengthening: isometric, isotonic, isokinetic exercise
Decreased stamina: aerobic exercise should be progressive with increase in du
Avascular necrosis
Nonoperative management in more advanced cases (bracing, crutches, intra-a
Surgical management, including joint replacement
PEDIATRIC CONSIDERATIONS
In children, a major goal is to avoid early replacement with artiﬁcial joints that
children involves appropriate chronic analgesia and a variety of temporizing
resurfacing at centers specializing in these approaches.prophylaxis for HSV in patients with chronic GVHD. If a pa-
tient with chronic GVHD is exposed to varicella (either pri-
mary or post-vaccination illness), VZV immunoglobulin, if
available, should be given within 96 hours, or valacyclovir
may be given until 22 days from exposure.
The optimal strategy to monitor and treat CMV after
day þ100 has not been deﬁned. Patients who begin chronic
GVHD therapy who also have lymphopenia and/or a history
of CMV reactivation during the ﬁrst 3 months after HCTare at
higher risk of late CMV reactivation and death [118]. Some
centers continue tomonitor for CMV viremia after day 100 by
weekly or every other week PCR testing based on individual
risks, followed by pre-emptive therapy, as follows:
 CMV seronegative (both donor and recipient): no
prophylaxis or viremia checks.
 CMV seropositive (either donor or recipient)s, Ster
tretchi
ration
rticula
have a
surgicaBNo prior history of CMV infection: CMV viremia
testing every 1 to 4 weeks
BHistory of CMV infection or disease: weekly CMV
viremia testing and pre-emptive treatment as during
the ﬁrst 100 days
BBecause of the high risk for CMV reactivation among
seropositive cord blood recipients, some centers
recommend prophylaxis with valganciclovir after
day 100 until 1 year after transplantation [119].Some investigators advocate early empirical treatment of
inﬂuenza with neuraminidase inhibitors during inﬂuenza
outbreaks, using prediction rules based on symptoms and
signs [120,121] although no evidence is available to support
this practice.
For speciﬁc dispensing information, please see
Supplement 9.
MUSCULOSKELETAL
Musculoskeletal complications after HCT are caused by
chronic GVHD and its treatment with corticosteroids. The
most frequent problems include fasciitis, sclerotic contrac-
tures and limitation in the ROM, steroid-induced myopathy,
and osteoporosis. The topic of fasciitis and sclerotic changes
has been partially covered under Skin and Appendages.
This section will focus on rehabilitation for disorders of
mobility associated with fasciitis, contractures, and steroidoid Myopathy, and Avascular Necrosis
Rating
ng exercises and to monitor progress. AIII
AIII
AIII
AIII
DIII
AII
and resistance to achieve elevated heart rate AIII
r steroids, oral medications) DIIb
BIIb
ﬁnite lifespan. Therefore, therapy for moderate to severe AVN in
l interventions including core decompression, partial or total hip
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nia/osteoporosis and avascular necrosis.
Rehabilitation in Patients with Chronic GVHD
Impairments such as joint contractures, limb swelling,
muscle atrophy, and weakness are often seen in chronic
GVHD. Functional loss associated with these impairments
includes decreased mobility, fatigue, decreased ability to
perform activities of daily living or work-related activities
[122,123]. Assessment of the patient depends on compre-
hensive neuromusculoskeletal examination testing strength,
ROM of affected joints, limb girth, pain, mobility, stamina,
activities of daily living, and subjective measures of disability
(Table 12). Whenever possible, treatment should be aimed at
early intervention and prevention of severe joint contrac-
tures and deconditioning. Restoration of ROM, strength, and
mobility and relief of pain are some of the essential reha-
bilitation goals [124-126]. Options include aggressive phys-
ical therapy and a home-based exercise program, along with
strong encouragement and provision of resources for regular
strength training and aerobics. These considerations
emphasize the importance of multidisciplinary teams in
managing chronic GVHD, with important contributions
sometimes being needed from physical medicine and reha-
bilitation (PM&R), as well as physical and occupational
therapy.
Patients with chronic glucocorticoid use are at risk of
developing avascular necrosis (AVN), with the femoral and
humeral heads being commonly involved. AVN results from
the destruction of the bony vasculature, and damage that
involves collapse of the articular surface is generally pro-
gressive and permanent. Plain ﬁlms of the joints can be
diagnostic, whereas magnetic resonance imaging is more
sensitive and typically the investigation of choice in the
setting of high clinical suspicion and normal x-ray ﬁndings.
AVN can lead to painful joints with restricted ROM.
Nonsurgical interventions are generally ineffective, except
for in patients with asymptomatic AVN and less than 15%
bony involvement on radiographs. In patients who are
healthy enough to tolerate surgery, joint replacement should
be considered [127].
Prevention and Management of Osteoporosis
Bone mineral metabolism is disturbed following
allogeneicHCT, evenbeyond6 years [128-131]. Abnormalities
include increased bone resorption and decreased bone
formation, with consequent osteopenia and, less frequently,
osteoporosis [132-134]. The recommendations for preventionTable 13
Recommendations for Prevention and Management of Osteoporosis
Recommendation
Calcium and vitamin D replacement in deﬁcient states, post-menopausal wome
Antiresorptive therapy when prolonged corticosteroid administration (>3 mo)
Antiresorptive therapy
In patients off steroids, T-score  1.5 with other potential fracture risks (con
In patients with higher T-scores
Weight-bearing exercise
Spinal orthosis for unstable compression fractures
PEDIATRIC CONSIDERATIONS
The deﬁnition of reduced BMD in children uses age and sex- normalized standa
osteoporosis requires the presence of clinically signiﬁcant fracture history and
lead to inappropriate misdiagnosis and over-treatment.
The use of bisphosphonates in children remains controversial because of inadequ
use to those children with reduced BMD, recurrent extremity fractures, and/oand treatment of osteoporosis in patients with chronic GVHD
are based on experience with osteoporosis in other diseases
such as breast and prostate cancer, and on expert consensus
(Table 13).
In patients with chronic GVHD, a baseline calcium (total
and ionized) and vitamin D level should be measured. These
tests should be repeated at least annually when normal or as
clinically indicated when abnormal or predicted to become
abnormal. The consideration of secondary causes of osteo-
porosis at this stage is also critical. Referral to an endocri-
nologist is warranted whenever an endocrine, secondary
cause of osteoporosis, such as hyperparathyroidism, is sus-
pected [130].
Bone mineral density (BMD) measurement by dual-
energy x-ray absorptiometry scans is recommended in
patients with chronic GVHD. The resulting T score indicates
the number of standard deviations above or below the
average BMD for average healthy young adults. T scores
< 1.5 indicate osteopenia, and T scores <2.5 indicate
osteoporosis. BMD studies should be repeated yearly for the
ﬁrst 3 years after HCT, and if BMD is stable, every 2 to 3 years
thereafter [130]. The online “FRAX” or “FORE” 10-year
fracture risk calculators are available to help guide the
need for antiresorptive therapy in adults, but these have
not been validated speciﬁcally for the HCT population: FRAX
(http://www.shef.ac.uk/FRAX/tool.aspx), FORE (https://
riskcalculator.fore.org).
Management consists of calcium and vitamin D supple-
mentation and antiresorptive therapy.
Calcium and vitamin D
Replacement is justiﬁed in deﬁcient states or when pa-
tients are post-menopausal or at high risk of developing
deﬁciency [135,136] but is not adequate in patients with
osteoporosis [137].
Antiresorptive therapy
In patients where steroid therapy is expected to last more
than 3 months, a BMD study should be performed and
antiresorptive therapy should strongly be considered espe-
cially in adults at high risk for fractures (see aforementioned
dental considerations in oral section). Preferred anti-
resorptive therapy includes hormonal replacement in those
who are deﬁcient and, in females between menarche and
approximately 50 years of age, or bisphosphonates [137-
139]. Secondary options include raloxifene or calcitonin
[137]. Newer agents include teriparatide, for which there is
randomized controlled data in non-HCT settings [140], andRating
n, and all at high risk of deﬁciency AIb
AIIb
sider FRAX or FORE risk calculators) AIIb
DIII
AIIb
AIIb
rd-deviation scores (Z-scores) rather than T scores. The diagnosis of
a BMD Z-score<2.0. The incorrect application of T-scores to childrenmay
ate long-term efﬁcacy and safety data. Therefore, many experts limit their
r symptomatic vertebral collapse; most experience is with pamidronate.
Table 14
Ancillary Therapy and Supportive Care Recommendations for Psychosocial Issues
Type of Intervention Rating
Brief neuropsychological testing if symptoms of cognitive deﬁcits disrupt daily activities and safety BII
Depression, anxiety and transplantation-related worry or distress: screen before transplantation, at 6 and 12 mo, and then annually
with referral for cognitive, behavioral interventions, or psychiatry assessment if indicated.
BII
Education for all adults at discharge on the importance of return to sexual activity, use of lubricants for women, and regular exercise
for management of sexual functioning, body image, sleep, fatigue and musculoskeletal symptoms. Query at 6 and 12 mo, then annually
with medical evaluation or referral to supportive and cognitive behavioral interventions if indicated.
CIII
Regularly assess level of caregiver psychological adjustment and functioning. CIII
PEDIATRIC CONSIDERATIONS
Neuropsychological evaluation is recommended if cognitive deﬁcits are suspected.
For mood, behavioral, academic, and adaptive functioning difﬁculties, screen before transplantation, at 6 and 12 mo, and then annually with referral
for cognitive behavioral interventions as indicated.
For body image issues and fatigue, query at 6 and 12 mo, and then annually with referral for cognitive behavioral and supportive interventions
as indicated. Attend to timing for addressing sexual function needs as adolescents develop.
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cancer patients and phase II trials in cancer patients [141].
However, the lack of experience after HCT led the working
group to recommend endocrine consultationwhen preferred
options cannot be used.
In patients who are not taking steroids for extended pe-
riods of time, recommendations are based on BMD T scores.
Antiresorptive therapy is frequently indicated if the BMD T
score is < 1.5. Patients with T scores > 1.5 should be
followed closely with BMD studies yearly for 3 years, and if
stable, every 2 to 3 years thereafter.
Weight-bearing exercise
Weight-bearing exercise, such as walking in 20- to 30-
minute bursts with rest periods in between, improves bone
density in osteopenic and osteoporotic patients [142].
Referral to a physical therapist or PM&R physician should be
considered in patients who cannot perform this routine
independently.
Vertebral compression fractures
Spinal orthotic bracing should be initiated if intractable
pain or evidence of neurologic compromise are present or if
the spine is unstable. Early mobilization with the brace and
tight pain control are the ﬁrst priority in management of
these patients. A consult with a spine surgeon and PM&R
physician should be strongly considered.
For speciﬁc dispensing information, please see
Supplement 10.PSYCHOSOCIAL
Studies of late effects in patients after allogeneic HCT
suggest that chronic GVHD produces deleterious conse-
quences for multidimensional functioning and quality of life
[143-145]. Patients with chronic GVHD report signiﬁcantly
more fatigue, pain, bowel changes, and dyspareunia than
those without chronic GVHD [145,146]. Lower physical, sex-
ual, and psychosocial functioning [144,145,147,148], along
with a lower likelihood of returning to work, are common in
patients with chronic GVHD, and patients with more severe
chronic GVHD have impaired physical and psychosocial re-
covery both at 1 year after HCT [149] and long term [150].
Chiodi et al. [151] reported that chronic GVHD was the
most important factor inﬂuencing diminished vocation and
domestic role function, negatively affecting family in-
teractions and social activities. Corticosteroid treatment was
independently associated with global distress [152]. Some of
the more prevalent psychosocial domains associated withchronic GVHD include neurocognitive impairment, depres-
sion, anxiety, altered body image, sexual dysfunction, and
fatigue [145,152-154].Neurocognitive Functioning, Depression, and Anxiety
Neurocognitive performance for motor dexterity, pro-
cessing speed, executive functioning, and memory [155] is
below population averages in 20% to 40% of adults immedi-
ately before HCT. Cognitive performance usually declines
further shortly after HCT yet recovers to its immediate pre-
transplantation levels in most patients by 1 year [154].
However, by 5 years after transplantation, 38% continue to
show mild impairment and 3% moderate impairment, pri-
marily in motor dexterity, verbal learning, and memory
[154]. Chronic GVHD has not been associated with any spe-
ciﬁc intellectual function deﬁcits, and immunosuppressive
medications have not been speciﬁcally examined as risk
factors. The research on pediatric neurocognitive perfor-
mance is mixed. Some studies document no cognitive effects
of transplantation, whereas others point to immediate or
slowly evolving impairment over time, mostly in processing
speed, attention, visual memory, and ﬁne motor coordina-
tion [156-160]. Contributing factors may include total body
irradiation conditioning regimen, young age at HCT, and
severity of GVHD [161].
Neuropsychological assessment may be helpful when
individuals perceive cognitive impairment in a nonspeciﬁc
way and clarity is needed to guide rehabilitative efforts.
However, consensus on the recommended test battery has
not yet been reached [162]. Because self-reported neuro-
cognitive function does not correlate reliably with objective
measures [163], adults should be referred for full neuropsy-
chological evaluation if warranted by initial screening or by
persisting concerns that cognition is disrupting functioning
rather than for general complaints of impaired cognition
(Table 14). For children, HCT potentially interrupts develop-
ment and even mild impairment may be compounded over
time by chronic GVHD or illness-related lack of opportunity
to learn and practice skills. Therefore, in children, neuro-
psychological evaluation at 1 year and annual targeted brief
screenings thereafter are advisable if any cognitive or
learning deﬁcits are identiﬁed.
Depressive symptoms are associated with chronic GVHD
and are more severe and longer term among those with
extensive chronic GVHD [145]. Depressed mood warrants
careful regular monitoring because it is the principal factor
associated with suicidal ideation, it is associated with mul-
tiple other negative outcomes, and can be effectively treated
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compared with that in the general population, and among
allogeneic HCT survivors, chronic GVHD increases this risk by
almost 3-fold [164,165].Sexual Dysfunction
Many patients acknowledge interruption of sexual activ-
ity and sexual difﬁculties for prolonged periods of time after
HCT. Recovery of sexual activity and quality of sexual func-
tion generally occurs within 2 years after HCT for men but
may persist longer or be permanent for women and for some
men [166]. Over 40% of females remain sexually inactive
even 5 years after treatment [167], and chronic GVHD in-
creases this risk for both men and women [168]. Contrib-
uting factors include GVHD of the skin and genitalia,
hormonal changes, and glucocorticoid therapy [147,169].
Phosphodiesterase type 5 inhibitors for men and brief ther-
apeutic options for sexual dysfunction in this population are
understudied but are beginning to demonstrate efﬁcacy in
other cancer populations [170-172]. Education on use of lu-
bricants should be universal for women after HCT. Dilators or
vibrators may be necessary to maintain or improve vaginal
dilation in women with chronic GVHD. Encouraging gradual
resumption of sexual activities is also important. Behavioral
treatments help to address a variety of problems. These
treatments can improve communication and intimacy and
help overcome anxiety about sexual desirability and con-
cerns about performance [147]. Hormone evaluation and the
need for hormone therapy warrant consultation with gyne-
cology or endocrinology as indicated.Fatigue and Musculoskeletal Symptoms
Although the biochemical, physiological, psychological,
and behavioral mechanisms of fatigue are not fully under-
stood [173], fatigue is a prevalent and distressing symptom
for many years after allogeneic HCT [150,174]. Over two
thirds of 5-year transplantation survivors report moderate to
severe fatigue, muscle weakness or myalgias, and muscle
cramps [175] (see also Table 10). Patients with ongoing
chronic GVHD have signiﬁcantly worse fatigue than those
without a history of GVHD or those whose GVHD had
resolved, in the absence of signiﬁcant differences in sleep
disturbance between groups [146]. Immunosuppressive
agents used to treat or prevent GVHD may differentially
contribute to fatigue [176].
Management of fatigue and musculoskeletal symptoms
includes a gradually increasing exercise regimen, activity
pacing, other cognitive behavioral strategies, and sometimes
medication. Detailed recommendations are available in the
National Comprehensive Cancer Network Clinical Practice
Cancer Survivorship Guidelines [177].Behavioral Interventions
Survivors with chronic GVHD often have unrecognized
psychological, functional, or adjustment difﬁculties. The
small evidence base for interventions for psychosocial issues
after HCT is limited to cognitive-behavioral interventions
[178,179], which have demonstrated efﬁcacy [179]. Mind-
fulness and cognitive behavioral stress-reduction in-
terventions have shown promise in cancer patients [180,181]
in general and could be helpful for patients coping with
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Strength of the Recommendation:
Category Deﬁnition
A Should always be offered.
B Should generally be offered.
C Evidence for efﬁcacy is insufﬁcient to support a
recommendation for or against, or evidence for efﬁcacy
might not outweigh adverse consequences, or cost of the
approach. Optional.
D Moderate evidence for lack of efﬁcacy or for adverse
outcome supports a recommendation against use. Should
generally not be offered.
E Good evidence for lack of efﬁcacy or for adverse outcome
supports a recommendation against use. Should never be
offered.
Quality of Evidence Supporting the Recommendation:
Category Deﬁnition
I Evidence from at least one properly randomized, controlled
trial.
II Evidence for at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies
(preferable from more than one center) or from multiple
time-series or dramatic results from uncontrolled experiments.
III Evidence from opinions of respected authorities based on
clinical experience, descriptive.
Qualiﬁer for Categories I and II
a Evidence derived directly from study(s) in GVHD
b Evidence derived indirectly from study(s) in analogous or
other pertinent disease
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